Clinical Trial Update: Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement [Phase 2]

View source ↗

Summary

This entry notes a Phase 2 trial evaluating low-dose oral imatinib for pulmonary involvement in systemic sclerosis (scleroderma); the trial status is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: Azienda Ospedaliera Universitaria Policlinico | Conditions: Systemic Sclerosis | Phase 2 | Status: UNKNOWN